Jazz Pharmaceuticals (JAZZ): Upside Is Clear - Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Jazz Pharmaceuticals (JAZZ) PT Lowered to $174 at Deutsche Bank; 'Decent Q, 2017 shaping up nicely'
May 10, 2017 9:06 AM EDTDeutsche Bank lowered its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $174.00 (from $176.00) while maintaining a Buy rating.
... More